Original article: Vonoprazan a novel potassium-competitive acid blocker as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III randomised double-blind study

摘要

ObjectiveThe objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a component of Helicobacter pylori eradication therapy.